A federal judge in Trenton has dismissed antitrust claims against drug makers Pfizer Inc. and Ranbaxy Pharmaceuticals Inc. over a deal the two companies struck to delay production of a generic version of the popular statin drug Lipitor.

U.S. District Judge Peter Sheridan said drug wholesalers and retailers who sued Pfizer and Ranbaxy failed to prove that the defendants engaged in anticompetitive conduct when they struck the deal that postponed the launch of generic Lipitor.